Monte Rosa Therapeutics (GLUE) said Wednesday it has closed its development and commercialization license deal with Novartis (NVS) for VAV1-directed molecular glue degraders, including MRT-6160.
Under the terms, Novartis will attain rigths to develop, produce, and commercialize MRT-6160 and other VAV1 molecular glue degraders, Monte Rosa added.
Novartis will carry out the phase 2 clinical trials, while Monte Rosa is in charge of completing the current phase 1 clinical study of MRT-6160, Monte Rosa said.
The clinical-stage biotechnology company will receive a $150 million upfront payment from Novartis, it said, adding that it will co-fund phase 3 development and share any profits and losses from the production and commercialization of MRT-6160 in the US.
Monte Rosa is also eligible for up to $2.1 billion in development, regulatory and sales milestones after initiation of phase 2 studies. It can also earn tiered royalties on ex-US sales.
The agreement was first announced in October.
Shares of Monte Rosa jumped over 8% in recent Wednesday premarket activity, while Novartis' stock edged up by 0.1%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。